Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

FLAG-IDA as frontline induction improves outcomes in pediatric patients with core-binding factor or KMT2A-rearranged acute myeloid leukemia: A multicenter cohort study in southern China

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJian LiMZMincui ZhengSLSixi Liu

Discussion

Loading...

Member takes

Overview

Multicenter cohort study shows FLAG-IDA enhances overall survival in pediatric patients with AML, highlighting its efficacy over DAE.

Key Points

  • This study assesses the efficacy and safety of the FLAG-IDA regimen as frontline induction therapy for pediatric acute myeloid leukemia.
  • Multicenter retrospective study of 875 pediatric patients with de novo AML (2015–2023)
  • Compared FLAG-IDA induction (n=681) to DAE induction (n=194)
  • Evaluated complete remission, overall survival, event-free survival, and treatment-related mortality
  • FLAG-IDA showed a better 5-year overall survival of 79.6% compared to 69.3% for DAE (p=0.006)
  • In CBF-AML patients, FLAG-IDA improved 5-year overall survival to 90.4% versus 78.4% for DAE (p=0.031)
  • In KMT2A-rearranged AML, FLAG-IDA resulted in 80.8% survival compared to 61.3% for DAE (p=0.044)

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8a3https://doi.org/10.1182/blood-2025-5152
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparative outcomes of FLAG-based versus standard 3+7 induction therapy in adults with newly diagnosed acute myeloid leukemia: A systematic review and meta-analysis.2026
  2. 2FLAG-Based Versus Standard 7+3 Induction Therapy in Adults with Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis2026
  3. 3FLAG/FLAG-Ida Regimen in Secondary and Relapsed/Refractory Acute Myeloid Leukemia—Even in the Era of New Treatment Modalities Still a Significant Player2024 · 5 citations
  4. 4Therapy related core binding factor Acute Myeloid Leukemia (CBF-AML) responds favorably to fludarabine, cytarabine, GCSF (FLAG) based therapy: Exploratory Analysis from a Phase 2 trial2025
  5. 5Integrated analysis of genomics, molecular responses and outcomes of CBF-AML with FLAG based therapy on a phase 2 trial2026 · 1 citations